Last updated 3 months ago

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

725 patients around the world

Available in Puerto Rico

This is a Phase III, parallel, randomized, open-label, sponsor-blinded, 3-arm, multicenter, international study assessing the efficacy and safety of durvalumab + tremelimumab + TACE with or without lenvatinib compared with TACE alone in participants with locoregional HCC not amenable to curative therapy (eg, surgical resection, transplantation, or ablation).

AstraZeneca

725Patients around the world

This study is for people with

Liver Cancer

Hepatocellular Carcinoma

Requirements for the patient

To 120 Years

All Gender

Medical requirements

: No evidence of extrahepatic disease
Disease not amenable to curative surgery or transplantation or curative ablation but disease amenable to TACE
Child Pugh score class A
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment
Measurable disease by Modified Response Criteria in Solid Tumors (mRECIST) criteria
Adequate organ and marrow function

: History of symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardia arrhythmia
History of hepatic encephalopathy
Major portal vein thrombosis visible on baseline imaging
Uncontrolled arterial hypertension
Co-infection with HBV and HDV

StudyEMERALD-3

SponsorAstraZeneca

Study typeInterventional

Conditions

Hepatocellular Carcinoma

Requirements

To 120 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT05301842